Another presentation about the accuracy of PSMA PET for staging of localized prostate cancer. Sensitivity 40% / specificity 95%. PSMA PET should become SOC for high risk localized prostate cancer, and could significantly shift staging and change management. #ASCO20
Approximately 15 to 20% of gastric adenocarcinomas express HER2. In an RT, the antibody-drug conjugate led to higher response and longer overall survival than physician’s choice of therapy among patients with relapsed disease. #ASCO20
Sobrero et al, final results of IDEA adjuvant collaboration:
OS, DFS and toxicity results continue to support the use of 3m adjuvant CAPOX for the vast majority of stage III colon cancer pts.
#ASCO20
💥 #ASCO20#LCSM ADAURA
Clear improvement of DFS in favour OSI but many open questions are emerged.
DFS was highly significant, of course potentially practice changing but...
Would you feel safe to use Osi in adjuvant thinking about your patients/OS?
Updated results of Ph2 KeyNote-146 w/ Pembro-Lenvatinib in mRCC patients 2L/3L. Prior regimens: anti-PD1/L1 (100%), Anti-PD1/L1+anti-VEGFR (65%) and Ipi-Nivo (37%). Very high ORR 55%, including all cohorts #ASCO20. Should this combo be tested in 2L/3L in Ph3 trials?
#1 GI cancer practice-changing data in #ASCO20: total neoadjuvant therapy in rectal cancer.
RAPIDO, PRODIGE, OPRA: TNT ⬆️pCR, ⬆️DFS, 3-y organ preservation in up to 59% pts.
Questions:
- Is triplet necessary?
- Is short course RT reasonable as organ preservation strategy?
Thank you Stashers for uniting for an epic run. You all claimed over 55,000 fractional shares of stock today!
See you at tomorrow’s #StashStockParty...and #MayThe4thBeWithYou... ⭐️⚔️
https://t.co/96ocgRtnHN
#StashStockParty presents The Cantina After-Party
☠️⭐️🚀💥⚔️🧙♂️🎲🌑🍹🎺🎶🌌
---------------------------------------
• 4 parties tomorrow, every 30 min
• Bring allies to boost the $$$
• Follow @Stash to stay briefed
---------------------------------------
⬇️⬇️⬇️#Maythe4th⬇️⬇️⬇️